Imfinzi (durvalumab) Market Report 2026

Imfinzi (durvalumab) Market Overview

• The Imfinzi (durvalumab) market growth in the historic period has been driven by clinical success of immune checkpoint inhibitors, rising lung cancer prevalence • Market expansion is supported by expansion into new cancer indications, increased immunotherapy accessibility • Growth Driver: Impact Of Rising Cancer Incidence On The Future Growth Of The Avelumab Market • Market Trend: Perioperative Immunotherapy Expansion Driving Competitive Differentiation In Advanced Oncology Care • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Imfinzi (durvalumab) Market?

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy drug specifically designed to block programmed death-ligand 1 (PD-L1), a protein that tumors use to evade detection by the immune system. It is used to treat various cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma. The main types of Imfinzi (durvalumab) are 2.4 mL injection and 10 mL injection. A 2.4 mL injection refers to a specific volume of a medication or therapeutic substance contained in a 2.4 milliliter (mL) vial or syringe, typically used for precise dosing in medical treatments or procedures. It can be distributed through hospital pharmacies, retail pharmacies, and online pharmacies for various applications, including locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and others.

What Is The Imfinzi (durvalumab) Market Growth Forecast?

The imfinzi (durvalumab) market size is expected to see rapid growth in the next few years. It will grow to $5.11 million in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to expansion into new cancer indications, increased immunotherapy accessibility, growth in oncology clinical trials, rising healthcare oncology spending, development of combination protocols. Major trends in the forecast period include rising adoption of pd-l1 inhibitors, expansion of immunotherapy in lung cancer, growth of combination immuno oncology regimens, increased focus on biomarker driven therapies, broader use across multiple solid tumors.

Global Imfinzi (durvalumab) Market Segmentation

1) By Type: 2.4mL Injection, 10mL Injection 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Other Applications

What Are The Drivers Of The Imfinzi (durvalumab) Market?

The growing incidence of cancer is expected to drive the growth of the Imfinzi (durvalumab) market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade and destroy normal tissues. The growing incidence of cancer is largely driven by an aging population, as the risk of cancer increases with age, and by lifestyle factors such as smoking, poor diet, and obesity, which contribute to higher cancer rates. Durvalumab (Imfinzi) is used to treat cancer by inhibiting the PD-L1 protein, which prevents cancer cells from evading detection by the immune system. For instance, in May 2024, according to the National Cancer Institute (NIH), a US-based government agency, in 2022, there were 18.1 million cancer survivors in the U.S., expected to rise to 22.5 million by 2032. Therefore, the growing incidence of cancer is driving the growth of the Imfinzi (durvalumab) industry. Rising personalized medicine is expected to propel the growth of the imfinzi (durvalumab) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Imfinzi (durvalumab), by targeting and inhibiting the PD-L1 protein, helps personalized medicine by enabling tailored immunotherapy treatments for cancer patients based on the specific tumor biology and immune system characteristics, thereby enhancing treatment efficacy and minimizing unnecessary side effects. For instance, in 2023, according to the Personalized Medicine Coalition, a US-based representative organization, in 2022, the FDA approved personalized medicines for 34% of new drugs, and during the previous eight years, they had been approved for at least 25% of new drugs. Therefore, rising personalized medicine drives the imfinzi (durvalumab) industry.

Key Players In The Global Imfinzi (durvalumab) Market

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

Global Imfinzi (durvalumab) Market Trends and Insights

Major companies operating in the Global Imfinzi (durvalumab) market are focusing on indication expansion, such as perioperative use combined with chemotherapy, to gain a competitive advantage. For instance, in January 2023, AstraZeneca plc, a UK based biopharmaceutical company, announced that IMFINZI plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone, featuring two phase treatment (pre surgery and post surgery) and a durable immune activation benefit. This broadening into gastrointestinal cancer settings underscores AstraZeneca’s strategy to deepen its clinical footprint and drive long-term uptake. However, this strategy also brings regulatory risk, as the more complex treatment regimens require additional trial data and health economic validation.

Regional Insights

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Imfinzi (durvalumab) Market?

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Imfinzi (durvalumab) Market Report 2026?

The imfinzi (durvalumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.